BioCardia
Overview
Products
Pipeline
Publications & Talks
Video

Science Publications & Talks

Shortcuts: 2013   2012   2011   2010   2009   2008   2007   2005   

2013
Paper

Heldman AW, Difede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, Mushtaq M, Williams AR, Suncion VY, McNiece IK, Ghersin E, Soto V, Lopera G, Miki R, Willens H, Hendel R, Mitrani R, Pattany P, Feigenbaum G, Oskouei B, Byrnes J, Lowery MH, Sierra J, Pujol MV, Delgado C, Gonzalez PJ, Rodriguez JE, Bagno LL, Rouy D, Altman P, Foo CW, da Silva J, Anderson E, Schwarz R, Mendizabal A, Hare JM. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: The TAC-HFT randomized trial. JAMA. 2013

Paper

Suncion VY, Ghersin E, Zambrano JP, Karantalis V, Mandel NS, Nelson KH, Fishman JE, Gerstenblith G, Velazquez DLD, Breton E, Schulman IH, Sitammagari K, Johnston PV, Brinker J, Altman P, Mushtaq M, Trachtenberg B, Silva JD, McNiece IK, Lardo AC, George RT, Hare JM, Heldman AW. Does transendocardial injection of mesenchymal stem cells improve myocardial function locally, or globally: An analysis from the POSEIDON trial. Journal of the American College of Cardiology. 2013;61

Paper Penn MS, Mendelsohn FO, Schaer GL, Sherman W, Farr M, Pastore J, Rouy D, Clemens R, Aras R, Losordo DW. An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure. Circulation research. 2013;112:816-825
Poster Wong Po Foo C, Ikeno F, Altman P, Rouy D. Quantifying therapeutic cell retention in the heart to compare three routes of local delivery: Transendocardial intramyocardial injection, transepicardial intramyocardial injection, and intracoronary artery infusion. 8th International Conference on Cell Therapy for Cardiovascular Disease. 2013
Poster Rouy D, Wong Po Foo C, Altman P. Training on transendocardial delivery: The helical infusion system experience. 8th International Conference on Cell Therapy for Cardiovascular Disease. 2013
Presentation Altman P. The helical infusion system. 8th International Conference on Cell Therapy for Cardiovascular Disease. 2013

2012
Paper

Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW, George R, Lardo A. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The poseidon randomized trial. JAMA. 2012;308:2369-2379

Paper Kumar A, Haralampus CA, Hughes M, Rouy D, Cresswell N, Braun R, Turner D, Amrani D, Motlagh D, Schaer GL. Assessment of safety, accuracy, and human cd34+ cell retention after intramyocardial injections with a helical needle catheter in a porcine model. Catheter Cardiovasc Interv. 2013;81:970-977
Presentation Penn MS, Mendelsohn FO, Schaer GL, Sherman W, Farr M, Pastore JM, Aras R, Rouy D, Clemens R, Cotts W. Re-establishment of sdf-1 expression through non-viral gene therapy improves clinical parameters through 12 months in patients with ischemic class iii heart failure. Journal of cardiac failure. 2012;18:S59-S60
Presentation

Penn MS. Sdf-1 for heart failure: One-year results of a phase i trial. 7th International Conference on Cell Therapy for Cardiovascular Disease. 2012


2011
Paper de la Fuente LM, Stertzer SH, Argentieri J, Penaloza E, Koziner B, Rouy D, Altman PA. Transendocardial autologous bone marrow in myocardial infarction induced heart failure, two-year follow-up in an open-label phase i safety study (the tabmmi study). EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2011;7:805-812
Presentation

Snow D. Helix transendocardial delivery catheter system, safety and ease of use after 100+ cases. 8th International Symposium on Stem Cell Therapy and Cardiovascular Innovation. 2011

Poster

De la Fuente L, Stertzer S, Argentieri J, Penaloza E, Koziner B, Wong Po Foo C, Rouy D, Altman P. Five year follow-up in heart failure safety study of transendocardial autologous bone marrow cell therapy delivered using helical infusion system provides first data that supports reduced mortality. 8th International Symposium on Stem Cell Therapy & Cardiovascular Innovations. 2011

Paper Trachtenberg B, Velazquez DL, Williams AR, McNiece I, Fishman J, Nguyen K, Rouy D, Altman P, Schwarz R, Mendizabal A, Oskouei B, Byrnes J, Soto V, Tracy M, Zambrano JP, Heldman AW, Hare JM. Rationale and design of the transendocardial injection of autologous human cells (bone marrow or mesenchymal) in chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction (tac-hft) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. Am Heart J. 2011;161:487-493
Presentation

De la Fuente L, Stertzer S, Argentieri J, Penaloza E, Miano J, Koziner B, Bilos C, Battaglia L, Lucero G, Stertzer J, Rouy D, Altman P. Five year follow-up in heart failure safety study of transendocardial autologous cell therapy derived from bone marrow delivered using helical infusion system provides first data that supports reduced mortality. Catheterization and Cardiovascular Interventions. 2011;77:F-030

Presentation

Penn M, Pastore J, Aras R, Rouy D, Schaer G, Farr M, Sherman W, Mendelsohn F, Losordo D. Initial results from first-in-man study delivering non-viral gene therapy jvs-100 to treat ischemic heart failure. Mol Ther. 2011;19:S1-S332

Paper

Williams AR, Trachtenberg B, Velazquez DL, McNiece I, Altman P, Rouy D, Mendizabal AM, Pattany PM, Lopera GA, Fishman J, Zambrano JP, Heldman AW, Hare JM. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling. Circ Res. 2011;108:792-796


2010
Poster Mendelsohn F, Pastore J, Miller T, Aras R, Penn M. Intramyocardial administration of jvs-100 promotes cardiac benefit and improves angiogenesis in a porcine model of heart failure. BIT 3rd Annual World Congress of Regenerative Medicine & Stem Cells. 2010
Paper

Dib N, Menasche P, Bartunek JJ, Zeiher AM, Terzic A, Chronos NA, Henry TD, Peters NS, Fernandez-Aviles F, Yacoub M, Sanborn TA, Demaria A, Schatz RA, Taylor DA, Fuchs S, Itescu S, Miller LW, Dinsmore JH, Dangas GD, Popma JJ, Hall JL, Holmes DR, Jr., International Society for Cardiovascular Translational R. Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: A report of the international society for cardiovascular translational research. JACC. Cardiovascular interventions. 2010;3:265-275


2009
Poster De la Fuente L, Stertzer S, Penaloza E, Argentieri J, Miano J, Koziner B, Bilos C, Battaglia L, Lucero G, Stertzer J, Rouy D, Altman P. Three-year follow-up in an open-label, pilot study of transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter. Cardiovascular revascularization medicine : including molecular interventions. 2009;10:273

2008
Presentation

De La Fuente L, Stertzer S, Penaloza E, Argentieri J, Miano J, Koziner B, Bilos C, Battaglia L, Stertzer J, Altman P. Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter, two year follow-up in an open-label, non-randomized, pilot study (the tabmmi study). Circulation. 2008;118:e162-e413

Poster

de la Fuente L, Stertzer SH, Penaloza E, Argentieri J, Miano J, Koziner B, Bilos C, Battaglia L, Lucero G, Stertzer J, Rouy D, Altman PA. Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: Two-year follow-up in an open-label, nonrandomized, pilot study (the tabmmi study): A first in man cell therapy trial with new delivery catheter technology. Cardiovascular Revascularization Medicine. 2008;9:111-112

Paper

Rodriguez-Porcel M, Brinton TJ, Chen IY, Gheysens O, Lyons J, Ikeno F, Willmann JK, Wu L, Wu JC, Yeung AC, Yock P, Gambhir SS. Reporter gene imaging following percutaneous delivery in swine moving toward clinical applications. J Am Coll Cardiol. 2008;51:595-597


2007
Paper

Rouy D, Miller A, Rosenman D, Peliks B, Palmer O, Gutierez F, Altman P. Transendocardial catheter delivery of biopolymer matrices for enhanced cell retention in cardiovascular cell-based therapy. 4th Annual Symposium of the American Heart Association Council on Basic Cardiovascular Sciences: Cardiovascular Repair and Regeneration: Structural and Molecular Approaches in the Cellular Era. 2007;101:e53-e77, P73 (567)

Paper de la Fuente LM, Stertzer SH, Argentieri J, Penaloza E, Miano J, Koziner B, Bilos C, Altman PA. Transendocardial autologous bone marrow in chronic myocardial infarction using a helical needle catheter: 1-year follow-up in an open-label, nonrandomized, single-center pilot study (the tabmmi study). Am Heart J. 2007;154:79 e71-77

2005
Paper

Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S, Durand DJ, Fitton T, Kuang JQ, Stewart G, Lehrke S, Baumgartner WW, Martin BJ, Heldman AW, Hare JM. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A. 2005;102:11474-11479